174 related articles for article (PubMed ID: 30122081)
1. Cost-effectiveness of somatostatin analogues in the treatment of acromegaly.
Orlewska E; Stępień R; Orlewska K
Expert Rev Pharmacoecon Outcomes Res; 2019 Feb; 19(1):15-25. PubMed ID: 30122081
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of second-line pharmacological treatment of acromegaly in Spain.
Peral C; Cordido F; Gimeno-Ballester V; Mir N; Sánchez-Cenizo L; Rubio-Rodríguez D; Rubio-Terrés C
Expert Rev Pharmacoecon Outcomes Res; 2020 Feb; 20(1):105-114. PubMed ID: 31055976
[No Abstract] [Full Text] [Related]
3. Pasireotide and Pegvisomant Combination Treatment in Acromegaly Resistant to Second-Line Therapies: A Longitudinal Study.
Chiloiro S; Bima C; Tartaglione T; Giampietro A; Gessi M; Lauretti L; Anile C; Colosimo C; Rindi G; Pontecorvi A; De Marinis L; Bianchi A
J Clin Endocrinol Metab; 2019 Nov; 104(11):5478-5482. PubMed ID: 31219586
[TBL] [Abstract][Full Text] [Related]
4. Cost-Utility of Acromegaly Pharmacological Treatments in a French Context.
Brue T; Chanson P; Rodien P; Delemer B; Drui D; Marié L; Juban L; Salvi L; Henocque R; Raverot G
Front Endocrinol (Lausanne); 2021; 12():745843. PubMed ID: 34690933
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological Acromegaly Treatment: Cost-Utility and Value of Information Analysis.
Leonart LP; Riveros BS; Krahn MD; Pontarolo R
Neuroendocrinology; 2021; 111(4):388-402. PubMed ID: 32299084
[TBL] [Abstract][Full Text] [Related]
6. [Epidemiology of acromegaly in Spain].
Sesmilo G
Endocrinol Nutr; 2013 Oct; 60(8):470-4. PubMed ID: 23246411
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of acromegaly treatments: a systematic review.
Leonart LP; Borba HHL; Ferreira VL; Riveros BS; Pontarolo R
Pituitary; 2018 Dec; 21(6):642-652. PubMed ID: 30159696
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of preoperative treatment of acromegaly with somatostatin analogue on surgical outcome.
Margusino-Framiñán L; Pertega-Diaz S; Pena-Bello L; Sangiao-Alvarellos S; Outeiriño-Blanco E; Pita-Gutierrez F; Pita-Fernandez S; Cordido F
Eur J Intern Med; 2015 Nov; 26(9):736-41. PubMed ID: 26300269
[TBL] [Abstract][Full Text] [Related]
9. Combined treatment of somatostatin analogues with pegvisomant in acromegaly.
Franck SE; Muhammad A; van der Lely AJ; Neggers SJ
Endocrine; 2016 May; 52(2):206-13. PubMed ID: 26661938
[TBL] [Abstract][Full Text] [Related]
10. Truncated somatostatin receptor 5 may modulate therapy response to somatostatin analogues--Observations in two patients with acromegaly and severe headache.
Marina D; Burman P; Klose M; Casar-Borota O; Luque RM; Castaño JP; Feldt-Rasmussen U
Growth Horm IGF Res; 2015 Oct; 25(5):262-7. PubMed ID: 26188991
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case report.
Ciresi A; Radellini S; Guarnotta V; Giordano C
BMC Endocr Disord; 2018 Jan; 18(1):2. PubMed ID: 29361932
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Controlled With Pegvisomant and First-Generation Somatostatin Analogues (PAPE Study).
Muhammad A; van der Lely AJ; Delhanty PJD; Dallenga AHG; Haitsma IK; Janssen JAMJL; Neggers SJCMM
J Clin Endocrinol Metab; 2018 Feb; 103(2):586-595. PubMed ID: 29155991
[TBL] [Abstract][Full Text] [Related]
13. Combination treatment with somatostatin analogues and pegvisomant in acromegaly.
Neggers SJ; van der Lely AJ
Growth Horm IGF Res; 2011 Jun; 21(3):129-33. PubMed ID: 21498099
[TBL] [Abstract][Full Text] [Related]
14. Prolonged preoperative treatment of acromegaly with Somatostatin analogs may improve surgical outcome in patients with invasive pituitary macroadenoma (Knosp grades 1-3): a retrospective cohort study conducted at a single center.
Duan L; Zhu H; Xing B; Gu F
BMC Endocr Disord; 2017 Sep; 17(1):55. PubMed ID: 28874187
[TBL] [Abstract][Full Text] [Related]
15. Multi-modal management of acromegaly: a value perspective.
Kimmell KT; Weil RJ; Marko NF
Pituitary; 2015 Oct; 18(5):658-65. PubMed ID: 25557288
[TBL] [Abstract][Full Text] [Related]
16. Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone.
van der Lely AJ; Bernabeu I; Cap J; Caron P; Colao A; Marek J; Neggers S; Birman P
Eur J Endocrinol; 2011 Mar; 164(3):325-33. PubMed ID: 21148630
[TBL] [Abstract][Full Text] [Related]
17. Budget impact of pasireotide LAR for the treatment of acromegaly, a rare endocrine disorder.
Zhang JJ; Nellesen D; Ludlam WH; Neary MP
J Med Econ; 2016; 19(4):374-85. PubMed ID: 26629745
[TBL] [Abstract][Full Text] [Related]
18. Medical Treatments for Acromegaly: A Systematic Review and Network Meta-Analysis.
Leonart LP; Ferreira VL; Tonin FS; Fernandez-Llimos F; Pontarolo R
Value Health; 2018 Jul; 21(7):874-880. PubMed ID: 30005760
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of lanreotide Autogel in treatment algorithms of acromegaly.
Biermasz NR; Roelfsema F; Pereira AM; Romijn JA
Expert Rev Pharmacoecon Outcomes Res; 2009 Jun; 9(3):223-34. PubMed ID: 19527094
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin analogs as a first-line treatment in acromegaly: when is it appropriate?
Grasso LF; Pivonello R; Colao A
Curr Opin Endocrinol Diabetes Obes; 2012 Aug; 19(4):288-94. PubMed ID: 22627686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]